Lipocine Inc. (LPCN) income statement
LPCNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3039% below fair value
$1.52−0.08 (-5.00%)
Close on Nov 18, 2026Market cap $12.53MP/E –Yield –
Lipocine Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- -800.8%
- Net margin
- -755.1%
- Return on equity, FY2025
- -54.3%
Financial strength
- Current ratio
- 11.48
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 240.8%
Valuation
- P/E ratio
- –
- Price to sales
- 7.98
- Price to book
- 0.58
- Dividend yield
- –
See a number that looks wrong?